secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2024-09-19T23:59:59+00:00
Accession:  0001213900-24-080268
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director Ilan Shiloah resigns from Silexion Therapeutics board effective Sept 16, 2024
--------------------------------------------------------------------------------

- Ilan Shiloah resigned as independent director and from audit, compensation, and governance committees.
- Resignation effective September 16, 2024; cited competing time demands.
- No disagreement with company operations, policies, or practices stated.
- Shiloah served since business combination closing on August 15, 2024.
- No replacement named at this time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000121390024080268/0001213900-24-080268-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000121390024080268/ea0215110-8k_silexion.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-080268

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer